Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 3:35 PM
Ignite Modification Date:
2025-12-24 @ 3:35 PM
NCT ID:
NCT00276692
Eligibility Criteria:
DISEASE CHARACTERISTICS:
* Histologically confirmed Ewing's tumor
* Ewing's sarcoma or peripheral primitive neuroectodermal tumor of bone or soft tissue
* High-risk disease (R3), defined as metastases at extrapulmonary/pleural sites
* Newly diagnosed disease
* Measurable primary and/or metastatic disease
* At least one bidimensionally measurable lesion
* Concurrent enrollment on EURO-Ewing99 clinical trial required
PATIENT CHARACTERISTICS:
* No abnormal cardiac function, including any of the following:
* Fractional shortening \< 29%
* Ejection fraction \< 40%
* Glomerular filtration rate ≥ 60mL/min
* Not pregnant
* Negative pregnancy test
* Fertile patients must use effective contraception during and for 3 months after completion of study treatment
* No prior or current history of chronic diarrhea, bowel obstruction, sub obstruction, Crohn's disease, or ulcerative colitis
* No other medical, psychiatric, or social condition incompatible with the study treatment
PRIOR CONCURRENT THERAPY:
* No prior chemotherapy
* No more than 45 days since prior definitive biopsy
Healthy Volunteers:
False
Sex:
ALL
Maximum Age:
19 Years
Study:
NCT00276692
Study Brief:
Protocol Section:
NCT00276692